Skip to main content
Premium Trial:

Request an Annual Quote

Agendia Breast Cancer Tests Adopted by French Hospital Group

NEW YORK (GenomeWeb) – Agendia said today that French hospital group Unicancer has selected its MammaPrint and BluePrint tests for use in a group of 18 comprehensive cancer centers.

The agreement includes centralized testing performed by Agendia in its CLIA-certified, CAP-accredited Amsterdam lab, as well as the provision of next-gen sequencing MammaPrint BluePrint kits, which hospital labs can run in house.

Marjolaine Baldo, Agendia's commercial vice president, EMEA, said in a statement that Unicancer's adoption of its tests is a "significant milestone."

The company promotes MammaPrint and BluePrint as complementary assays, providing both risk and molecular subtyping information. MammaPrint analyzes 70 genes associated with breast cancer recurrence to provide a binary low or high risk of cancer recurrence to help physicians decide which individuals can forgo chemotherapy. BluePrint includes 80 genes and classifies a patient's breast cancer into one of four functional molecular subtypes.

Agendia received a CE mark for the NGS kit-version of its tests — which uses Agilent Technologies' SureSelect target enrichment system — in March.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.